PainReform Stock (NASDAQ:PRFX)

Ownership Financials Chart

Previous Close

$0.61

52W Range

$0.57 - $20.16

50D Avg

$1.47

200D Avg

$6.90

Market Cap

$714.33K

Avg Vol (3M)

$395.89K

Beta

0.54

Div Yield

-

PRFX Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

7

IPO Date

Sep 01, 2020

Website

PRFX Performance

PRFX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	$86.00K	-
Operating Income	$-9.58M	$-8.87M	$-7.21M
Net Income	$-9.34M	$-8.79M	$-7.25M
EBITDA	$-9.57M	$-8.71M	$-7.21M
Basic EPS	$-7.14	$-8.25	$-7.38
Diluted EPS	$-7.14	$-8.25	$-7.38

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
FLGC	Flora Growth Corp.
QLI	Qilian International Holding Group Limited
UPC	Universe Pharmaceuticals INC
RGC	Regencell Bioscience Holdings Limited
INCR	InterCure Ltd.
CLVR	Clever Leaves Holdings Inc.
PROC	Procaps Group S.A.
JUPW	Safety Shot Inc
EGRX	Eagle Pharmaceuticals, Inc.